|
|
Blood, 1 July 2004, Vol. 104, No. 1, pp. 115-122.
Prepublished online as a Blood First Edition Paper on March 4, 2004; DOI 10.1182/blood-2003-07-2456.

Submitted July 22, 2003
Accepted February 21, 2004
Preventing re-stimulation of memory B cells in hemophilia A: A potential new strategy for the treatment of antibody-dependent immune disorders ?
Christina Hausl, Rafi U Ahmad, Hans Peter Schwarz, Eva M Muchitsch, Peter L Turecek, Friedrich Dorner, and Birgit M Reipert*
Immunology, BMT-Research, Vienna, Austria; Immunology, Technical University, Vienna, Austria
Research and Development, Baxter BioScience, Vienna, Austria
Immunology, BMT-Research, Vienna, Austria; Research and Development, Baxter BioScience, Vienna, Austria
* Corresponding author; email: birgit_reipert{at}baxter.com.
Memory B cells are responsible for the rapidly emerging antibody response after antigen re-exposure. The signals required for the re-stimulation of memory B cells have not been fully explained. We used a murine model of anti-factor VIII (FVIII) antibody responses in hemophilia A to study the requirements for the re-stimulation of FVIII-specific memory B cells and their differentiation into anti-FVIII antibody-producing cells. We were particularly interested in the significance of activated T cells and co-stimulatory interactions. Our results indicate that the re-stimulation of FVIII-specific memory B cells is strictly dependent on interactions with activated T cells. These activated T cells can be specific for either FVIII or third-party antigens. Re-stimulation by T cells specific for third-party antigens requires the presence of FVIII indicating that signals induced by B-cell receptor (BCR) triggering and by interactions with activated T cells are important. The blockade of B7-1 or B7-2 as well as the blockade of CD40L inhibits the re-stimulation and differentiation of FVIII-specific memory B cells in vitro and in vivo. The interference with ICOS-ICOSL interactions, however, does not cause any modulation. As expected, the production of anti-FVIII antibodies by plasma cells is not dependent on any of the co-stimulatory interactions tested.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.-N. Boivin, K. Doody, M. Tremblay, et al.
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction
Blood,
December 15, 2008;
112(13):
4991 - 4998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Peng, P. Ye, B. R. Blazar, G. J. Freeman, D. J. Rawlings, H. D. Ochs, and C. H. Miao
Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice
Blood,
September 1, 2008;
112(5):
1662 - 1672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lacroix-Desmazes, A.-M. Navarrete, S. Andre, J. Bayry, S. V. Kaveri, and S. Dasgupta
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A
Blood,
July 15, 2008;
112(2):
240 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Allacher, C. Hausl, R. U. Ahmad, H. P. Schwarz, P. L. Turecek, and B. M. Reipert
Toll-Like Receptor Triggering Modulates Factor VIII-Specific Immune Memory in Murine Hemophilia A with Factor VIII Inhibitors.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
214 - 214.
[Abstract]
|
 |
|

|
 |

|
 |
 
C. Hausl, R. U. Ahmad, M. Sasgary, C. B. Doering, P. Lollar, G. Richter, H. P. Schwarz, P. L. Turecek, and B. M. Reipert
High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors
Blood,
November 15, 2005;
106(10):
3415 - 3422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hausl, R. U. Ahmad, M. Sasgary, C. B. Doering, P. S. Lollar, G. Richter, H. P. Schwarz, P. L. Turecek, and B. M. Reipert
Inhibition of Factor VIII-Specific Memory B Cell Responses by Supra-Physiological Concentrations of Factor VIII.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
38 - 38.
[Abstract]
|
 |
|
|
|